Efungumab
Efungumab Usage And Synthesis
Uses
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC)[1].
in vivo
Efungumab (2 mg/kg, i.p., daily for 3 days) significantly decreases mean organ colony counts and increases negative liver biopsies for many of the isolates in CD1 mice models of disseminated c. albicans disease[2].
| Animal Model: | CD1 mice models of disseminated c. albicans disease[2] |
| Dosage: | 2 mg/kg, daily for 3 days |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates. |
References
[1] Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. DOI:10.1345/aph.1M218
[2] Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23. DOI:10.1073/pnas.0813394106
EfungumabSupplier
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 15971444841
- amber@biochempartner.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com